General Information of Drug (ID: DME25TI)

Drug Name
Prosaptide TX14(A) Drug Info
Synonyms Prosaptide; TX-14(A)
Indication
Disease Entry ICD 11 Status REF
Neuropathic pain 8E43.0 Phase 2 [1]
Cross-matching ID
PubChem CID
16197909
TTD Drug ID
DME25TI

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug(s) Targeting Receptor unspecific (Rec)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ATL-104 DMD0I29 Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
Lactermin DM8ANIM Oral mucositis DA01.11 Phase 1 [4]
BT-063 DMS4H30 Autoimmune diabetes 5A10 Phase 1 [5]
PV-707 DMRODZS Skin burns ME65.0 Discontinued in Phase 2 [6]
YP-004 DMK1UJM Solid tumour/cancer 2A00-2F9Z Terminated [7]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Receptor unspecific (Rec) TTDB5IS NOUNIPROTAC Modulator [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6067).
2 Central action of prosaptide TX14(A) against gp120-induced allodynia in rats. European Journal of Pain Volume 12, Issue 1, January 2008, Pages 76-81.
3 Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebo-controlled trial. Bone Marrow Transplant. 2009 Apr;43(7):563-9.
4 Mammalian lactoferrin receptors: structure and function. Cell Mol Life Sci. 2005 Nov;62(22):2560-75.
5 Clinical pipeline report, company report or official report of Biotest.
6 EP patent application no. 1904089, Promotion of epithelial regeneration.
7 CA patent application no. 815512, Method for increasing the efficiency of double-strand break-induced mutagenesis.